Anti-Gephyrin antibody (ab83765)


  • Product nameAnti-Gephyrin antibody
    See all Gephyrin primary antibodies
  • Description
    Rabbit polyclonal to Gephyrin
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Cat, Dog, Zebrafish
  • Immunogen

    Synthetic peptide corresponding to a region within the N terminal amino acids 179-228 (HDELEDLPSP PPPLSPPPTT SPHKQTEDKG VQCEEEEEEK KDSGVASTED) of Human Gephyrin (NP_001019389).

  • Positive control
    • 721_B cell lysate.



Our Abpromise guarantee covers the use of ab83765 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 85 kDa (predicted molecular weight: 80 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.
ELISA Use at an assay dependent concentration.

ELISA titre using peptide based assay 1/1562500.


  • FunctionMicrotubule-associated protein involved in membrane protein-cytoskeleton interactions. It is thought to anchor the inhibitory glycine receptor (GLYR) to subsynaptic microtubules (By similarity). Catalyzes two steps in the biosynthesis of the molybdenum cofactor. In the first step, molybdopterin is adenylated. Subsequently, molybdate is inserted into adenylated molybdopterin and AMP is released.
  • PathwayCofactor biosynthesis; molybdopterin biosynthesis.
  • Involvement in diseaseDefects in GPHN are the cause of molybdenum cofactor deficiency type C (MOCOD type C) [MIM:252150]. MOCOD type C is an autosomal recessive disease which leads to the pleiotropic loss of all molybdoenzyme activities and is characterized by severe neurological damage, neonatal seizures and early childhood death.
    Defects in GPHN are a cause of startle disease (STHE) [MIM:149400]; also known as hyperekplexia. STHE is a genetically heterogeneous neurologic disorder characterized by muscular rigidity of central nervous system origin, particularly in the neonatal period, and by an exaggerated startle response to unexpected acoustic or tactile stimuli.
  • Sequence similaritiesIn the N-terminal section; belongs to the moaB/mog family.
    In the C-terminal section; belongs to the moeA family.
  • Cellular localizationCell junction > synapse. Cell junction > synapse > postsynaptic cell membrane. Cytoplasm > cytoskeleton. Cytoplasmic face of glycinergic postsynaptic membranes.
  • Information by UniProt
  • Database links
  • Alternative names
    • Domain E antibody
    • Domain G antibody
    • GEPH antibody
    • GEPH_HUMAN antibody
    • GPH antibody
    • GPHN antibody
    • GPHRYN antibody
    • KIAA1385 antibody
    • Molybdopterin molybdenumtransferase antibody
    • MPT adenylyltransferase antibody
    • MPT Mo-transferase antibody
    see all

Anti-Gephyrin antibody images

  • Anti-Gephyrin antibody (ab83765) at 1 µg/ml + 721_B cell lysate at 10 µg

    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size : 80 kDa
    Observed band size : 85 kDa (why is the actual band size different from the predicted?)

References for Anti-Gephyrin antibody (ab83765)

ab83765 has not yet been referenced specifically in any publications.

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Zebrafish Tissue lysate - whole (Brain)
Loading amount 10 µg
Specification Brain
Gel Running Conditions Reduced Denaturing (10%)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Dr. Ayça Arslan Ergül

Verified customer

Submitted Dec 31 2012

Expiration date: DD MM YYYY

I am very pleased to hear you would like to accept our offer and test ab83765 in Zebrafish. This code will give you the value of ab83765 off your next order before the expiration date. To re...

Read More